MX2016011420A - Peptidos horquilla beta con propiedades antivirales contra el virus dengue. - Google Patents

Peptidos horquilla beta con propiedades antivirales contra el virus dengue.

Info

Publication number
MX2016011420A
MX2016011420A MX2016011420A MX2016011420A MX2016011420A MX 2016011420 A MX2016011420 A MX 2016011420A MX 2016011420 A MX2016011420 A MX 2016011420A MX 2016011420 A MX2016011420 A MX 2016011420A MX 2016011420 A MX2016011420 A MX 2016011420A
Authority
MX
Mexico
Prior art keywords
beta
dengue virus
properties against
viral properties
peptides
Prior art date
Application number
MX2016011420A
Other languages
English (en)
Other versions
MX363745B (es
Inventor
Acosta Osvaldo Reyes
Santiago Glay Chinea
Blanco Sonia González
López Luis Javier González
Galindo Vivian Huerta
Dunn Alejandro Miguel Martín
Cruz Osmany Guirola
Pérez Hilda Elisa Garay
NÚÑEZ Mónica SARRÍA
CAMA Viviana FALCÓN
PUPO GÓMEZ Dianne
Jesús MÁRQUEZ PERERA Gabriel
Yero Díaz Alexis
GARATEIX SUÁREZ Rocío
Alvarez Pérez Karen
VÁZQUEZ CASTILLO Mariela
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2016011420A publication Critical patent/MX2016011420A/es
Publication of MX363745B publication Critical patent/MX363745B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con péptidos sintéticos, estructuralmente constreñidos, que han sido optimizados para la formación de estructura horquilla beta; dichos péptidos son capaces de inhibir o atenuar la infección por el virus Dengue (DENV); la invención incluye también composiciones farmacéuticas que contienen estos péptidos sintéticos, las que son útiles para la prevención y/o el tratamiento de las infecciones causadas por DENV; de igual forma, la invención provee un método de tratamiento de las infecciones causadas por este virus.
MX2016011420A 2014-03-03 2015-02-26 Peptidos horquilla beta con propiedades antivirales contra el virus dengue. MX363745B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CUP2014000026A CU20140026A7 (es) 2014-03-03 2014-03-03 Péptidos horquilla beta con propiedades antivirales contra el virus dengue
PCT/CU2015/000002 WO2015131858A2 (es) 2014-03-03 2015-02-26 Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Publications (2)

Publication Number Publication Date
MX2016011420A true MX2016011420A (es) 2016-11-16
MX363745B MX363745B (es) 2019-04-01

Family

ID=53008223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011420A MX363745B (es) 2014-03-03 2015-02-26 Peptidos horquilla beta con propiedades antivirales contra el virus dengue.

Country Status (14)

Country Link
US (1) US9896482B2 (es)
EP (1) EP3115056B1 (es)
JP (1) JP6854644B2 (es)
KR (1) KR102325400B1 (es)
CN (1) CN106132981B (es)
AR (1) AR099563A1 (es)
AU (1) AU2015226580B2 (es)
CA (1) CA2940078C (es)
CU (1) CU20140026A7 (es)
ES (1) ES2733648T3 (es)
MX (1) MX363745B (es)
MY (1) MY181033A (es)
PH (1) PH12016501715B1 (es)
WO (1) WO2015131858A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310741A (zh) * 2016-04-29 2019-02-05 阿拉伊姆药品公司 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
CU23630A1 (es) * 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Also Published As

Publication number Publication date
MY181033A (en) 2020-12-16
BR112016019672A2 (pt) 2017-10-24
US9896482B2 (en) 2018-02-20
KR102325400B1 (ko) 2021-11-12
WO2015131858A2 (es) 2015-09-11
ES2733648T3 (es) 2019-12-02
EP3115056A2 (en) 2017-01-11
KR20160127097A (ko) 2016-11-02
WO2015131858A3 (es) 2015-10-29
AU2015226580B2 (en) 2018-11-08
AU2015226580A1 (en) 2016-09-15
CN106132981B (zh) 2019-11-12
EP3115056B1 (en) 2019-04-03
JP2017509619A (ja) 2017-04-06
CA2940078C (en) 2020-11-17
CA2940078A1 (en) 2015-09-11
MX363745B (es) 2019-04-01
CN106132981A (zh) 2016-11-16
US20170152290A1 (en) 2017-06-01
CU20140026A7 (es) 2015-11-27
PH12016501715A1 (en) 2016-12-19
AR099563A1 (es) 2016-08-03
PH12016501715B1 (en) 2016-12-19
JP6854644B2 (ja) 2021-04-07

Similar Documents

Publication Publication Date Title
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201891970A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018015522A (es) Tratamiento de infeccion por clostridium difficile.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
NZ730809A (en) Methods for treating filoviridae virus infections
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
GB2541571A (en) Pharmaceutical compositions
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
MX2018015125A (es) Nuevos compuestos antibacterianos.
MX2015015506A (es) Peptidos antimicrobianos.
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX2017012073A (es) Compuestos de minociclina para biodefensas.
EP3166637A4 (en) Compositions and methods for treating dengue virus infection
IN2014CH00840A (es)
IN2014MU00916A (es)
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12016502000B1 (en) Novel bacteriophage and composition comprising same
EA201790851A1 (ru) Способы предотвращения, уменьшения и лечения макулодистрофии
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds

Legal Events

Date Code Title Description
FG Grant or registration